News Update: GenoBioTX and Crown Bioscience Sign Global Cooperation Agreement
20240627
GenoBioTX and Crown Bioscience have entered into a five-year global partnership, enhancing their existing collaboration. This agreement leverages GenoBioTX's vast animal model resources and Crown Bioscience's specialized immuno-oncology platform to deliver superior model resources and CRO services.
GenoBioTX will share its library of over 11,000 standardized genetically engineered mouse models with Crown Bioscience and provide development services for these models and cell lines. This collaboration aims to advance immuno-oncology research and bridge the gap between scientific discovery and clinical application, invigorating the global biopharmaceutical industry.
About Crown Bioscience
Founded in 2006, Crown Bioscience is now a subsidiary of JSR Life Sciences. Headquartered in San Diego, California, Crown Bioscience operates 13 subsidiaries and R&D centers across the Americas, Europe, and Asia, employing over 1,200 people globally. As a preclinical CRO, Crown Bioscience specializes in providing preclinical and translational medicine platform services, focusing on oncology and immuno-oncology drug discovery and development. The company boasts an extensive, commercially viable PDX model library worldwide. Exclusively licensed by the Netherlands' HUB, Crown Bioscience offers tumor organoid commercialization services. Notably, in 2021, Crown Bioscience contributed to the approval of 6 out of 13 oncology drugs by the FDA. Crown Bioscience assists clients in selecting effective cancer drug candidates, ensuring timely and effective treatment for patients.
你也可能感兴趣
Cre-ERT2在无Tamoxifen诱导的情况下,在细胞质内处于无活性状态;当Tamoxifen诱导后,Tamoxifen的代谢产物4-OHT(雌激素类似物)与ERT结合,可使Cre-ERT2进核发挥Cre重组酶活性。
查看
